Opendata, web and dolomites

CerISMA

Cerenkov Imaging for Surgical Margin Assessment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CerISMA" data sheet

The following table provides information about the project.

Coordinator
LIGHTPOINT MEDICAL LTD 

Organization address
address: MISBOURNE WORKS WATERSIDE
city: CHESHAM
postcode: HP5 1PE
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://cerisma.com/
 Total cost 2˙351˙461 €
 EC max contribution 2˙351˙461 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIGHTPOINT MEDICAL LTD UK (CHESHAM) coordinator 2˙351˙461.00

Map

 Project objective

Cancer is not only a leading public health challenge in Europe, it is also a growing economic challenge. Over three million cases are currently diagnosed each year across the continent. Forecasts show that by 2020 almost half of the population will be diagnosed with the disease in their lifetime. The cost of cancer for the EU is €126 billion per year and rising. The health and economic implications of cancer therefore provide a compelling business opportunity for technologies that can improve health outcomes and reduce treatment costs.

Surgery remains one of the primary treatments for cancer, yet surgeons lack the tools to identify accurately and remove cancer during an operation, resulting in costly re-operations and negative health ramifications. Lightpoint Medical has developed a molecular imaging camera (LightPath™) based on a breakthrough imaging modality, Cerenkov Luminescence Imaging (CLI). The technology can provide surgeons with real time intraoperative analysis of cancerous tissue to ensure the complete removal of cancer in a single operation. The device provides the potential for a dramatic reduction in costly re-operations and adjuvant therapies across a wide range of major cancer indications, proving not only an innovative solution for healthcare providers, but also a tool to substantially reduce cancer care costs.

CerISMA is proposed as a multi-centre clinical trial to confirm the clinical efficacy of LightPath™ in a lead cancer indication and to evidence the health economic impact of the technology. The project is vital for the company’s growth, fundamentally underpinning the company’s ambitious sales and marketing strategy across strategic target territories in Europe and the US.

 Deliverables

List of deliverables.
Website developed Websites, patent fillings, videos etc. 2020-02-07 15:29:59
Initial Press Releases Documents, reports 2020-02-07 15:29:59

Take a look to the deliverables list in detail:  detailed list of CerISMA deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CERISMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CERISMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PNEUMOSIP (2015)

PNEUMOSIP

Read More  

OncoMasTR (2016)

OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More